Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Leases (2019 - 2026)

Integra Lifesciences Holdings' Leases history spans 11 years, with the latest figure at $140.6 million for Q4 2025.

  • On a quarterly basis, Leases fell 2.41% to $140.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $140.6 million, a 2.41% decrease, with the full-year FY2025 number at $140.6 million, down 2.41% from a year prior.
  • Leases hit $140.6 million in Q4 2025 for Integra Lifesciences Holdings, up from $138.2 million in the prior quarter.
  • Over the last five years, Leases for IART hit a ceiling of $156.8 million in Q3 2023 and a floor of $81.6 million in Q1 2022.
  • Historically, Leases has averaged $131.4 million across 5 years, with a median of $144.6 million in 2022.
  • Biggest five-year swings in Leases: fell 10.45% in 2022 and later surged 79.45% in 2023.
  • Tracing IART's Leases over 5 years: stood at $84.5 million in 2021, then skyrocketed by 75.39% to $148.3 million in 2022, then rose by 5.33% to $156.2 million in 2023, then decreased by 7.77% to $144.0 million in 2024, then fell by 2.41% to $140.6 million in 2025.
  • Business Quant data shows Leases for IART at $140.6 million in Q4 2025, $138.2 million in Q3 2025, and $136.6 million in Q2 2025.